Scolaris Content Display Scolaris Content Display

Corticosteroids for the treatment of Kawasaki disease in children

This is not the most recent version

References

Additional references

Ayusawa 2005

Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, et al. Kawasaki Disease Research Committee. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatrics International 2005;47(2):232‐4.

Baumer 2006

Baumer JH, Love SJ, Gupta A, Haines LC, Maconochie I, Dua JS. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD004175.pub2]

Brogan 2002

Brogan P, Bose A, Burgner D, Shingadia D, Tulloh R, Michie C, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Archives of Disease in Childhood 2002;86(4):286‐90.

Burns 1996

Burns JC, Shike H, Gordon JB, Malhotra A, Schoenwetter M, Kawasaki T. Sequelae of Kawasaki disease in adolescents and young adults. Journal of the American College of Cardiology 1996;28(1):253‐7.

Chen 2013

Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta‐analysis. Heart 2013;99(2):76‐82.

Daniels 2012

Daniels LB, Gordon JB, Burns JC. Kawasaki disease: late cardiovascular sequelae. Current Opinion in Cardiology 2012;27(6):572‐7.

Davies 2013

Davies S, Gold‐von Simson G. Should infliximab be used as an adjuvant to IVIG in the treatment of children with Kawasaki disease who are at high risk for resistance to conventional therapy?. Pediatric Cardiology 2013;34(7):1756.

Eleftheriou 2013

Eleftheriou D, Levin M, Shingadia D, Tulloh R, Klein NJ, Brogan PA. Management of Kawasaki disease. Archives of Disease in Childhood 2013;99(1):74‐83.

Gardner‐Medwin 2002

Gardner‐Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch‐Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002;360(9341):1197‐202.

Harnden 2002

Harnden A, Alves B, Sheikh A. Rising incidence of Kawasaki disease in England: analysis of hospital admission data. BMJ 2002;324(7351):1424‐5.

Hashino 2001

Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re‐treatment for immune globulin‐resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International 2001;43(3):211‐7.

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.

Hokosaki 2012

Hokosaki T, Mori M, Nishizawa T, Nakamura T, Imagawa T, Iwamoto M, et al. Long‐term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatrics International 2012;54(1):99‐103.

Holman 2003

Holman RC, Curns AT, Belay ED, Steiner CA, Schonberger LB. Kawasaki syndrome hospitalizations in the United States; 1997 and 2000. Pediatrics 2003;112(3 Pt 1):495‐501.

Jones 2008

Jones KS, Baumer JH, Gupta A, Dua JS. Steroid hormone treatment for Kawasaki disease in children. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD003284.pub2]

Kato 1979

Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63(2):175‐9.

Kato 1996

Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long‐term consequences of Kawasaki disease. A 10‐ to 21‐year follow‐up study of 594 patients. Circulation 1996;94(6):1379‐85.

Kawasaki 1967

Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967;16(3):178‐222.

Kobayashi 2008

Kobayashi T, Inoue Y, Morikawa A. Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease. Japanese Journal of Clinical Medicine 2008;66(2):332‐7.

Levin 1991

Levin M, Tizard EJ, Dillon MJ. Kawasaki disease: recent advances. Archives of Disease in Childhood 1991;66(12):1369‐72.

Levin 2013

Levin M. Steroids for Kawasaki disease: The devil is in the detail. Heart 2013;99(2):69‐70.

Nakamura 2012

Nakamura Y, Yashiro M, Uehara R, Sadakane A, Tsuboi S, Aoyama Y, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009‐2010 nationwide survey. Journal of Epidemiology 2012;22(3):216‐21.

Newburger 2004

Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long‐term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110(17):2747‐71.

Oates‐Whitehead 2003

Oates‐Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD004000]

RevMan 2014 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Sleeper 2011

Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD, et al. Pediatric Heart Network Investigators. Evaluation of Kawasaki disease risk‐scoring systems for intravenous immunoglobulin resistance. The Journal of Pediatrics 2011;158(5):831‐5, e3.

Tatara 1987

Tatara K, Kusakawa S. Long‐term prognosis of giant coronary aneurysm in Kawasaki disease: An angiographic study. The Journal of Pediatrics 1987;111(5):705‐10.

Wood 2009

Wood LE, Tulloh RM. Kawasaki disease in children. Heart 2009;95(10):787‐92.